INTENTIONALLY OMMITTED. 2.11.2 Licensee shall evaluate any new formulation developed by Ipsen pursuant to the MC4 [ ]* Agreement and shall give written notice to Ipsen if Licensee determines, in its sole and absolute discretion, that such new formulation meets the characteristics, profile and specifications provided by Licensee therefor set forth in the MC4 [ ]* development of MC4 Products. If Licensee gives such written notice to Ipsen with respect to any such new formulation, then such new formulation shall be referred to in this Agreement as the “Ipsen MC4 [ ]*”.
Appears in 5 contracts
Samples: License Agreement (Rhythm Pharmaceuticals, Inc.), License Agreement (Rhythm Pharmaceuticals, Inc.), License Agreement (Rhythm Pharmaceuticals, Inc.)
